Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
Ozpuyan
Fulya
F
Meyer
Paul
P
Ni
Hongyu
H
Al-Masri
Hytham
H
Alkan
Serhan
S
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D002470:Cell Survival / Q000187:drug effects; D015925:Cryopreservation; D003609:Dactinomycin / Q000031:analogs & derivatives / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005434:Flow Cytometry; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000473:pathology*; D011719:Pyrazines / Q000494:pharmacology*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D003609:Dactinomycin; D000069286:Bortezomib; C025942:7-aminoactinomycin D